Invitrogen Corporation

Incyte Genomics asserted sixteen patents, including U.S. Patent Nos. 5,807,522 and 6,110,426, which related to methods of fabricating microarrays of biological samples. Incyte sought injunctive relief, damages, treble damages for alleged willful infringement, fees, costs, and interest. The ultimate disposition of the case was not verified in the retrieved sources.